Alpha 2.0
Login Register
» Authors » Reyes Bernabe Caro

Reyes Bernabe Caro

Explore the profile of Reyes Bernabe Caro including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 2145
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Mariano Provencio
Jong-Seok Lee
Margarita Majem
Martin Reck
Alex Martinez-Marti
Manuel Domine
Delvys Rodriguez-Abreu
Amelia Insa
Julie R Brahmer
Suresh S Ramalingam
Published In
J Thorac Oncol
Lung Cancer
J Clin Oncol
N Engl J Med
Clin Transl Med
Affiliations
Soon will be listed here.
Recent Articles
11.
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, et al.
J Immunother Cancer . 2021 Aug; 9(8). PMID: 34446577
Background: Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains...
12.
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia Campelo M, Lazaro M, et al.
Clin Cancer Res . 2021 Aug; 27(21):5878-5890. PMID: 34376534
Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non-small cell lung cancer (NSCLC). Experimental...
13.
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
Laza-Briviesca R, Cruz-Bermudez A, Nadal E, Insa A, Del Rosario Garcia-Campelo M, Huidobro G, et al.
Clin Transl Med . 2021 Jul; 11(7):e491. PMID: 34323406
Background: Immunotherapy is being tested in early-stage non-small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR) as compared to standard of care. Early identification of...
14.
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
Garcia-Campelo R, Arrieta O, Massuti B, Rodriguez-Abreu D, Granados A, Majem M, et al.
Lung Cancer . 2020 Oct; 150:62-69. PMID: 33070053
Objectives: Progression-free survival (PFS) and response rate to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung cancer (NSCLC) driven byEGFR mutations, suggesting that...
15.
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Provencio M, Nadal E, Insa A, Garcia-Campelo M, Casal-Rubio J, Domine M, et al.
Lancet Oncol . 2020 Sep; 21(11):1413-1422. PMID: 32979984
Background: Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage...
16.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
Hellmann M, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S, Carcereny Costa E, et al.
N Engl J Med . 2019 Sep; 381(21):2020-2031. PMID: 31562796
Background: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with...